Celgene Corp (CELG) Tops Q2 EPS by 8c; REVLIMID Sales Rose 13%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CELG Hot Sheet
Price: $108.24 --0%
Financial Fact:
Research and development: 1.65B
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Research and development: 1.65B
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Celgene Corp (NASDAQ: CELG) reported Q2 EPS of $1.52, $0.08 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.56 billion versus the consensus estimate of $1.54 billion.
REVLIMID sales up 13 percent to $1.05 billion.
For earnings history and earnings-related data on Celgene Corp (CELG) click here.
REVLIMID sales up 13 percent to $1.05 billion.
For earnings history and earnings-related data on Celgene Corp (CELG) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- RBC Capital Reiterates Outperform Rating on Verisk Analytics (VRSK)
- Caldwell sells IQTalent subsidiary to WinMil for C$4.7M
Create E-mail Alert Related Categories
Earnings, Hot Corp. News, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
